Ulosteensiirto on tuonut apua etenkin Clostridium difficile -infektion hoitoon.

Suoliston bakteerien ja immuunivälitteisten sairauksien välillä on yhteys. Syy-yhteyttä ei tosin vielä tunneta. Tätä selvittelee parhaillaan meneillään oleva tanskalainen FLORA-tutkimus.

Sexual dysfunction is more common among men and women with Inflammatory Bowel Disease (IBD) than in the background population. Previous studies have shown that about 40-60% of women with IBD and up to 44% of men with IBD report sexual dysfunction.1,2 A recent meta-analysis by Zhao et al. of eight studies with control groups found that IBD was significantly associated with an elevated risk of sexual dysfunction in men (relative risk [RR]: 1.41; 95% CI: 1.09–1.8) and women (RR: 1.76; 95% CI: 1.28–2.42).3  Inflammatory bowel disease patients with a relatively young age (male: <50 years; female: <40 years) had significantly increased odds of sexual dysfunction compared with controls. Six of the studies in this meta-analysis used the “gold standard” Female Sexual Function Index (FSFI)4 and International Index of Erectile Function (IIEF)5 for comparison of sexual function in patients with IBD to that of individuals in the general population. The other…

Katsotuimmat MEDtalk-videot

ECCO 2019: Vedolizumab vs adalimumab in patients with active ulcerative colitis   Katso video

ECCO 2019: Vedolizumab vs adalimumab in patients with active ulcerative colitis

<script src="https://fast.wistia.com/embed/medias/b5rwewng4t.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_b5rwewng4t seo=false videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/b5rwewng4t/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
ECCO 2019: Vedolizumab vs adalimumab in patients with active ulcerative colitis&nbsp;&nbsp;&nbsp;<a href='https://bestprac.fi/webinar/ecco-2019-vedolizumab-vs-adalimumab-in-patients-with-active-ulcerative-colitis/'>Katso video

ECCO 2019: Vedolizumab and anti-TNF in Crohn’s disease are equally effective

<script src="https://fast.wistia.com/embed/medias/b5rwewng4t.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_b5rwewng4t seo=false videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/b5rwewng4t/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
ECCO 2019: Vedolizumab and anti-TNF in Crohn’s disease are equally effective&nbsp;&nbsp;&nbsp;<a href='https://bestprac.fi/webinar/ecco-2019-vedolizumab-and-anti-tnf-in-crohns-disease-are-equally-effective/'>Katso video

ECCO 2019: The cost burden of IBD dependent on biologic treatment status

<script src="https://fast.wistia.com/embed/medias/b5rwewng4t.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_b5rwewng4t seo=false videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/b5rwewng4t/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
ECCO 2019: The cost burden of IBD dependent on biologic treatment status&nbsp;&nbsp;&nbsp;<a href='https://bestprac.fi/webinar/ecco-2019-the-cost-burden-of-ibd-dependent-on-biologic-treatment-status/'>Katso video

ECCO 2019: Prevalence and healthcare costs of perianal fistulas in Crohn’s disease

<script src="https://fast.wistia.com/embed/medias/b5rwewng4t.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_b5rwewng4t seo=false videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/b5rwewng4t/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
ECCO 2019: Prevalence and healthcare costs of perianal fistulas in Crohn’s disease&nbsp;&nbsp;&nbsp;<a href='https://bestprac.fi/webinar/ecco-2019-prevalence-and-healthcare-costs-of-perianal-fistulas-in-crohns-disease/'>Katso video

In a Danish nationwide cohort of patients with CD, the prevalence of perianal fistulas decreased in the period from 2010 to 2016. The reason for this needs further elucidation. Only half of the incident cases received biologicals, yet biological treatment was the main expenditure for the entire study population. Healthcare costs for pCF decreased during the study period, but are still high compared with non-pCF IBD patients.  

This study, a register-based Danish population study, investigated the average annual healthcare costs and production values of patients 10 years before and 8 years after diagnosis, and after initiating biologic treatment.  

Patients with inflammatory bowel disease diagnosed in childhood are at an increased risk of both cancer and mortality compared to the background population. While cancer is the leading cause of death, the risk of suicide is markedly increased.  

#Tuorein julkaisu

Gastroenterologia

Nro. 11 • Toukokuu 2019
5. vuosikerta
  • Ulosteensiirto
  • Suolistosyöpä
  • IBD ja uupumus
#

Gastroenterologia

Airi Jussila,

Airi Jussila,
LT, erikoislääkäri,
gastroenterologian vastuualue

Heikki Huhtinen,

Heikki Huhtinen,
LT, erikoislääkäri

Olli-Pekka Koivurova,

Olli-Pekka Koivurova,
hallinnollinen apulaisylilääkäri

Jyrki Kössi,

Jyrki Kössi,
Kirurgian dosentti